CD8A and neoplasm: Transfer of the different PRAME TCRs to CD8+ T cells of four different donors resulted in efficient killing of OVCA tumor cell lines and the primary patient-derived OVCA cells (OVCA-L23 p0 or p10) (Figure 5A).